Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00463346
Recruitment Status : Completed
First Posted : April 20, 2007
Results First Posted : January 15, 2016
Last Update Posted : January 15, 2016
Forest Laboratories
Information provided by (Responsible Party):
Yale University

Brief Summary:

The aim of this study is to evaluate the safety and efficacy of acamprosate for patients with alcohol dependence and comorbid schizophrenia spectrum disorders.

  • 1: Relative to placebo, acamprosate will significantly increase cumulative days of abstinence in recently detoxified alcohol dependent schizophrenia patients measured by Timeline Follow-Back (TLFB) method.
  • 2: Acamprosate will have no significant effect on the psychotic symptoms in schizophrenia patients with alcohol dependence as measured by the Positive and Negative Syndrome Scale (PANSS).

Condition or disease Intervention/treatment Phase
Alcohol Dependence Schizophrenia Drug: Acamprosate Drug: Placebo Phase 3

Detailed Description:

Alcohol use disorders (AUD) are common comorbid conditions in patients with schizophrenia, and they cause a negative impact on the expression and course of schizophrenia. Improvements have been reported after attaining abstinence from alcohol, suggesting that effective treatments for AUD lead to clinically meaningful results. Acamprosate is a recently approved treatment for alcoholism, and it may be advantageous over other treatments since is not metabolized in the liver, and it has been used safely with other psychotropic medications. Therefore, acamprosate would be a promising treatment in schizophrenia patients. However, there are only few reports in the current literature evaluating the efficacy of medications available for the treatment of alcoholism in patients with schizophrenia, and the efficacy and safety of acamprosate have never been studied in this vulnerable group of patients.

Research Design:

This is a 12-week, randomized, double blind, placebo controlled trial of acamprosate (666 mg tid) in addition to neuroleptics in 30 recently abstinent (>5 days) schizophrenia patients with comorbid alcohol dependence.


The study will be conducted at the West Haven, CT VA with support from Forest Laboratories. Patients who are between 21 and 65, with a diagnosis of schizophrenia spectrum disorder, (on stable psychotropic treatment > 2 weeks) and with current alcohol dependence (>1 recent episode of heavy drinking) will be included. Patients will be willing to undergo detoxification or self discontinuation >2weeks prior to the randomization. Main outcome variables include the TLFB method to document the degree of daily alcohol consumption, and PANSS, to assess the psychotic symptoms.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
Study Start Date : September 2006
Actual Primary Completion Date : July 2015
Actual Study Completion Date : July 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Acamprosate
Drug: Acamprosate
Acamprosate 1998 mg tid
Other Name: Campral

Placebo Comparator: placebo
Drug: Placebo

Primary Outcome Measures :
  1. Number of Drinking Days [ Time Frame: 12 weeks ]
  2. Psychotic Symptoms - Measured Using the PANSS [ Time Frame: 12 weeks ]
    The PANSS or the Positive and Negative Syndrome Scale is a medical scale used for measuring symptom severity of patients with schizophrenia. The patient is rated from 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers. Of the 30 items included in the PANSS, 7 constitute a Positive Scale, 7 a Negative Scale, and the remaining 16 a General Psychopathology Scale.The scores for these scales are arrived at by summation of ratings across component items. Therefore, the potential ranges are 7 to 49 for the Positive and Negative Scales, and 16 to 112 for the General Psychopathology Scale. A higher score indicates more severe symptoms.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  1. Men and women between 21 and 65 years of age.
  2. Patients with a diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder NOS as determined by the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID) [22].
  3. Patients who are on stable treatment with psychotropic medication > 2 weeks prior to randomization.
  4. Patients with current alcohol dependence, with at least one recent episode of heavy drinking (defined as 5 or more drinks per drinking episode) over the past 21 days, and willing to undergo detoxification or self discontinuation (for at least 5 days).
  5. Patients, who are able to comprehend and satisfactorily comply with protocol requirements.
  6. Patients who have capacity to provide informed consent prior to entering any study procedure.

Exclusion Criteria

  1. Patients with dementia, amnestic and other cognitive disorders.
  2. Patients who have unstable medical disease or a medical condition that, in the Investigator's opinion, would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the course of the trial
  3. Patients with a history of opioid dependence within the past month.
  4. Patients with a history of intolerance or hypersensitivity to acamprosate.
  5. Patients who are currently taking disulfiram or naltrexone.
  6. Patients who based on history or mental status examination are at a significant risk for suicide.
  7. Patients who are homicidal or violent and who are in the Investigator's opinion in significant imminent risk of hurting others.
  8. Women who are pregnant or nursing, or women of childbearing potential who are sexually active and who do not use adequate contraception, or who are judged to be unreliable in their use of contraception.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00463346

United States, Connecticut
VA Connecticut Healthcare System
WEst Haven, Connecticut, United States, 06516
Sponsors and Collaborators
Yale University
Forest Laboratories
Principal Investigator: Ismene L Petrakis, MD Yale University

Responsible Party: Yale University Identifier: NCT00463346     History of Changes
Other Study ID Numbers: CMP-MD-13
First Posted: April 20, 2007    Key Record Dates
Results First Posted: January 15, 2016
Last Update Posted: January 15, 2016
Last Verified: December 2015

Keywords provided by Yale University:
Alcohol Dependence

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Alcohol Deterrents